Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Morepen Labs adds three new drugs - Rivaroxaban, Vildagliptin and UDCA to its API portfolio

Posted On: 2019-10-14 09:40:58


Morepen Laboratories Ltd. has developed and added three blockbuster drugs to its portfolio of Active Pharmaceutical Ingredients (APIs) for sale in domestic and global markets. The three bulk drugs I APis are Rivaroxa ban (trade name Xarelto), Vildagliptin (trade names - Galvus, Zomelis) and UDCA (Ursodeoxycholic Acid). While two products Rivaroxaban and Yildagliptin will augment Morepen's presence in the Cardiac and Diabetic segments respectively, the third product UDCA will cater to the Liver segment.

The current global market size for Rivaroxaban, a powerful anticoagulant (blood thinner), is $7.1 9 Billion (Rs. 51,000 cores) and that of Vildagliptin, which is a strong oral Anti-diabetic drug used for the treatment of type 2 diabetes, is $1.28 Billion (Rs. 9,000 cores). The global market size for Rivaroxaban is likely to touch $9.00 Billion(Rs. 64,000 crore) by year 2023 and that of Yildagliptin $1.35 Billion (Rs. 9,600 crore) by 2021. Morepen Labs will initially target patent free markets for these two drugs globally. The Drug Master File (DMF) for regulatory markets like US etc will be filed within the next 12 months' time frame.

This was disclosed by Mr. Sushil Suri, Chairman and Managing Director, Morepen Laboratories Ltd., here on Monday. "The company has already built-up additional capacities and is now all set to commercially launch these three new API's under its portfolio. Dedicated efforts of Morepen's in-house R&D Centre at Baddi (Himachal Pradesh), which was recently approved by Department of Scientific & Industrial Research, Govt. of India, has led to the release of these three products," he said.

"With a focus on new molecules, new patented processes, we now look forward towards investing more in our R&D Infrastructure for future growth of the company," Mr. Suri further pointed out.

Rivaroxaban is the 10th largest selling drug worldwide. It caters to the Cardiac market. It was initially developed and patented worldwide by Bayer. Morepen already has substantial presence in this category with two leading statins - Atorvastatin and Rosuvastatin that are aggressively being used for lowering cholesterol. Now with the addition of Rivaroxaban in Morepen's portfolio, company gets an added advantage in the cardiac market. The Indian patent for the drug is going to expire in Dec' 2019 which opens floodgates for the company to export the drug to all the patent free markets worldwide and also supply the product to the large domestic market where it is commonly used to prevent blood clots and used for cardiovascular symptoms such as angina, heart failure, rheumatic heart disease etc.

Vildagliptin caters to the Diabetics market worldwide. Morepen footprint in diabetic sector is well established with a series of "glilptins" like Sitagliptin, Linaglitptin, Saxagliptin and new series of"gliflozins" like Empagliflozin and Dapagliflozin, already developed by Morepen's R&D Centre. Development of low cost Vildagliptin, which is used for the treatment of metabolic disorders such as obesity, diabetes, PCOD & fatty liver etc., is a nice addition to growing Diabetic portfolio of the company. Vildagliptin patent is presently held by Novartis and this is set to expire worldwide in December 2019. Vildagliptin has about 25 per cent share of the Indian "gliptins" market of Rs. 3500 crore. Vildagliptin is the first molecule in the most commonly prescribed "gliptins" series that is going off patent and is certainly going to get good traction in the market.

UDCA is a niche product and has lot of technical challenges to synthesize. It is a naturally occurring product in the bile acid, found in normal human bile in small quantities. UDCA is used for the treatment of Primary Biliary Cirrhosis, a liver disease which occurs due to improper functioning of liver. It is also prescribed for the decrease in bile absorption, reduction in gallstone formation and also to relieve the symptoms of itching. UDCA has a niche market of $200million (Rs. 1,400 cores) and is expected to touch $300 million (Rs. 2,100 crore) by 2023. UDCA is already patent-free worldwide and ready for exporting across all the continents.

The bulk drugs (API) segment contributed marginally over 60 per cent to the company's total turnover in Q I FY 2019-20. API Exports grew by 50 percent during Q I and domestic API business grew by 33 per cent in the quarter. Morepen Labs has plans to invest in the areas of advance research related to new API molecules, patented technologies and new polymorphic form of the existing products. This will also give a big boost to the fresh R&D initiatives of the company for investing in future.

Shares of MOREPEN LABORATORIES LTD. was last trading in BSE at Rs.15.65 as compared to the previous close of Rs. 15.75. The total number of shares traded during the day was 50045 in over 127 trades.

The stock hit an intraday high of Rs. 16 and intraday low of 15.6. The net turnover during the day was Rs. 789933.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Lupin Ltd board recommends dividend of Rs. 6

IndiGo advises clients on fastest ways to access customer service

Lupin Ltd Q4 FY20 consolidated PAT at Rs. 389.63 crore

Wipro appoints Thierry Delaporte as CEO & Managing Director

ITC's B Natural and Amway India collaborate to launch first of its kind immunity offering in Fruit beverages, with clinically proven ingredient

NMDC is committed to Chhattisgarh

Agro Tech Foods Limited announces resignation of Chairperson

CRISIL revises ratings on bank facilities of Inox Wind Ltd

Acuité reaffirms rating of Swarnsarita Gems Limited

Agro Tech Foods Ltd Board recommends Final Dividend of Rs. 3 for FY20

Cadila Healthcare Ltd receives EIR for formulations facility at Baddi

Automobile Corporation of Goa Ltd Board recommends Final Dividend of Rs. 5

Agro Tech Foods Ltd Q4 consolidated net profit at Rs. 3.92 crore

Expleo Solutions Ltd consolidated Q4 FY20 PAT at Rs. 13.96 crore

CEAT Ltd Q4 FY2020 consolidated net profit at Rs. 51.88 crore

Rain Industries Ltd Q1 CY2020 consolidated PAT at Rs. 106.52 crore

Chembond Chemicals Ltd reports loss of Rs. 6.12 crore in Q4 FY20

HCL Technologies and Broadcom Expand Their Global Preferred Services Partnership to Include Symantec Enterprise Security Consulting

TCS Wins Two Stevie® Awards for 2019 TCS New York City Marathon App

Apollo Hospitals Enterprise Ltd board to consider Q4, Fy20 results on June 22, 2020

Ankit Metal & Power Ltd reappoints Mr. Ankit Patni as MD

Hindustan Oil Exploration Company Ltd board to approve Q4, FY20 results on May 31, 2020

SRF Ltd Board to consider FY20 results & Final Dividend on June 04, 2020

Muthoot Capital Services Ltd Q4 net profit lower at Rs. 13.90 crore

HeidelbergCement India Ltd Q4 PAT up at Rs. 66.29 crore

LT Foods Ltd posts Q4 FY2020 consolidated PAT of Rs. 53.98 crore

Wendt India posts sales of Rs. 12037 lakhs, net profit at Rs. 934 lakhs

Mindtree donates worth of Rs. 1.87 Crores, Covid-19 relief support materials and vehicles

D-LINK (INDIA) LIMITED updates on customs duty demand

Pidilite Industries Limited completes acquisition of shares of Tenax India Stone Products Pvt. Ltd

NHPC Limited to foray into development of Solar Power Projects

SPARC and Sun Pharma enter into a worldwide license agreement for SCD-044, a potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders

HeidelbergCement India Ltd Board approves Final Dividend for FY2019-20

TVS Motor Company Ltd Q4 FY20 consolidated net profit declines to Rs. 74.04 crore

Federal Bank Ltd reports consolidated Q4 FY20 PAT of Rs. 302.95 crore

Wendt India Ltd reports consolidated loss of Rs. 0.77 crore

Radico Khaitan Ltd Q4 FY20 PAT at Rs. 38.44 crore

Wendt India Ltd board recommends final dividend of Rs. 25

Brickwork Ratings downgrades the ratings of Tourism Finance Corporation of India Ltd

Radico Khaitan Ltd board recommends final dividend of Rs. 2

Nodwin Gaming and Airtel announce partnership to take Esports in India to the next level

Benares Hotels Ltd board recommends dividend of Rs. 7.5

Sukhjit Starch and Chemicals Ltd board to consider FY20 results, dividend on June 12, 2020

Capital India Finance Ltd board to consider Financial Results, Final Dividend and Raising Funds

Benares Hotels Ltd Q4 net profit at Rs. 4.34 crore

Prism Johnson Ltd reports earnings for FY2020

Steel Strips Wheels Ltd bags export orders for over 25,000 wheels

Dr. Reddy's Laboratories Ltd receives EIR from USFDA for IPDO facility

Intellect launches CALM 20, a unified contextual ALM platform to manage balance sheet risks

TCS Launches Cloud Solution to Help US Banks Manage Surge in Small Business PPP Loan Forgiveness







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019